Wenxin Keli for atrial fibrillation: Protocol for a systematic review and meta-analysis

    loading  Checking for direct PDF access through Ovid

Abstract

Background:

Atrial fibrillation (AF) is a most common cardiac arrhythmia in clinical practice. In China, Wenxin Keli (WXKL) therapy is a common treatment for AF, but its effects and safety remain uncertain. This protocol is to provide the methods used to assess the effectiveness and safety of WXKL for the treatment of patients with AF.

Methods:

We will search comprehensively the 4 English databases EMBASE, the Cochrane Central Register of Controlled Trials (Cochrane Library), PubMed, and Medline and 3 Chinese databases China National Knowledge Infrastructure (CNKI), Chinese Biomedical Literature Database (CBM), and Chinese Science and Technology Periodical database (VIP) on computer on March 2018 for the randomized controlled trials (RCTs) regarding WXKL for AF. The therapeutic effects according to the sinus rhythm and p-wave dispersion (Pwd) will be accepted as the primary outcomes. We will use RevMan V.5.3 software as well to compute the data synthesis carefully when a meta-analysis is allowed.

Results:

This study will provide a high-quality synthesis of current evidence of WXKL for AF.

Conclusion:

The conclusion of our systematic review will provide evidence to judge whether WXKL is an effective intervention for patient with AF.

PROSPERO registration number:

PROSPERO CRD 42018082045.

Related Topics

    loading  Loading Related Articles